Prostate Cancer

In a live event, Ganesh V. Raj, MD, PhD, discussed the drug-drug interactions and outcomes by disease volumes across ARPI trials in mHSPC.

The first patient was dosed in a phase 1/2 trial of evofosfamide with checkpoint inhibitors for hypoxia-reversal in resistant solid tumors.

The dose-escalation phase of the SECuRE trial in prostate cancer has completed and demonstrated promising safety and efficacy data.

A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to 80 patients.

In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering the recent data from the ARANOTE study.

The FDA has granted fast track status to 67Cu-SAR-bisPSMA for metastatic prostate cancer that is resistant to hormone therapy after prior treatment, based on SECuRE trial data.

Prostate-specific antigen responses were similar between transdermal estradiol and hormone therapy combined with androgen receptor inhibitors in prostate cancer.

CTCm from circulating tumor cells correlated with outcomes in mCRPC patients treated with bavdegalutamide in the ARDENT trial.

Radium-223 re-treatment is safe for metastatic castration-resistant prostate cancer, per findings from the 2025 ASCO GU Cancers Symposium.

Olaparib plus abiraterone improved survival vs placebo in BRCA-mutated metastatic castration-resistant prostate cancer.

Darolutamide plus ADT improved outcomes in metastatic hormone-sensitive prostate cancer, regardless of disease volume, in the phase 3 ARANOTE trial.

External beam radiation therapy with or without short-term androgen deprivation showed 15-year survival benefits for intermediate-risk prostate cancer.

Darolutamide with ADT and docetaxel benefits both younger and older patients with metastatic hormone-sensitive prostate cancer, per post hoc analysis.

Real-world data highlight gaps in genetic testing and targeted therapy use for metastatic castration-resistant prostate cancer, stressing need for improvement.

Talazoparib plus enzalutamide boosts overall survival in metastatic castration-resistant prostate cancer, with HRR-deficient patients seeing a 14-month gain and 38% lower death risk.

Daniel Rubin, PharmD, BCOP, discussed a study showing how a clinical decision support tool can improve the documentation of biomarker results in cancer care.

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients with metastatic hormone-sensitive prostate cancer.

The FDA granted fast track designation to 64Cu-SAR-bisPSMA for PET imaging of PSMA-positive prostate cancer lesions in patients with biochemical recurrence following definitive therapy.

In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.

The FDA set August 29, 2025, as the PDUFA date for the 3-month leuprolide mesylate formulation, supported by phase 3 trial data.

During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes presented at ESMO 2024 and how they fit into the treatment paradigm for patients with metastatic hormone-sensitive prostate cancer.

Data from the phase 3 CAPItello-281 trial showed that capivasertib plus abiraterone and androgen deprivation therapy significantly improved radiographic progression-free survival in patients with PTEN-deficient metastatic hormone-sensitive prostate cancer.

The FDA has accepted a supplemental new drug application for the combination of darolutamide and androgen deprivation therapy for the treatment of patients with metastatic hormone-sensitive prostate cancer.

The FDA has approved the investigational new drug application of AS1986NS for prostate cancer detection and treatment.

A new drug application for a 3-month depot formulation of leuprolide mesylate has been submitted to the FDA.

Bertram Yuh, MD, MISM, MSHCPM, discussed how single-port robotic surgery has changed treatment paradigms for patients with prostate cancer.

The phase 3 trial AMPLIFY study plans to test the diagnostic performance of 64Cu-SAR-bisPSMA PET/CT imaging in approximately 220 patients with prostate cancer with biochemical recurrence.

In this feature we spoke to Michael J. Morris, MD, and Benjamin Garmezy, MD, on the future of radioligand therapy in patients with prostate cancer.

According to findings from the TALAPRO-2 study, the combination led to significant and meaningful improvements in overall survival vs enzalutamide monotherapy.

The FDA has approved the WATER IV PCa trial, which will compare the safety and efficacy of Aquablation therapy to radical prostatectomy in patients with localized prostate cancer.